Coronavirus (COVID-19)
Learn more
April 11, 2017
Sponsor: Pharmacyclics LLC.
Number: PCYC-1137-CA
Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety. Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) to evaluate the efficacy of Ibrutinib in combination with Nab-Paclitaxel and Gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma (the development of secondary malignant growths at a distance from the primary site of cancer).
Who’s eligible:
Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209